Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients
- 31 January 2006
- journal article
- research article
- Published by Elsevier BV in Atherosclerosis
- Vol. 184 (1), 72-77
- https://doi.org/10.1016/j.atherosclerosis.2005.04.013
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Jama-Journal Of The American Medical Association, 2001
- Metabolic effects of indinavir in healthy HIV-seronegative menAIDS, 2001
- Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteersAIDS, 2001
- Comparison of P-Triglyceride Levels among Patients with Human Immunodeficiency Virus on Randomized Treatment with Ritonavir, Indinavir or Ritonavir/SaquinavirScandinavian Journal of Infectious Diseases, 2001
- Effect of ritonavir on lipids and post-heparin lipase activities in normal subjectsAIDS, 2000
- Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease InhibitorsCirculation, 1999
- Hyperlipidemia Associated with Protease Inhibitor TherapyAnnals of Pharmacotherapy, 1999
- Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsArchives of Internal Medicine, 1988
- Cholesterol and mortality. 30 years of follow-up from the Framingham studyPublished by American Medical Association (AMA) ,1987
- High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial.Circulation, 1986